Skip to main content
logo
Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
10.57
+0.32 (3.12%)
Nov 6, 2026, 4:00 PM EST - Market closed

Monte Rosa Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-130.97-38.63-72.7-135.35-108.5-73.96
Depreciation & Amortization
10.6810.8610.228.323.752.13
Loss (Gain) From Sale of Assets
--0.06--0.02-0.110.02
Loss (Gain) From Sale of Investments
-1.52-2.15-2.95-3.78-1.95-
Stock-Based Compensation
22.5518.8718.1316.6711.665.2
Other Operating Activities
-2.5-2.5-2.1-2.14.810.96
Change in Accounts Receivable
-2.66-4.430.331.9-0.19-
Change in Accounts Payable
-11.13-13.716.255.76-0.74-0.71
Change in Unearned Revenue
-13.337.5283.3850--
Change in Other Net Operating Assets
-36.591.421.4414.81-1.26.99
Operating Cash Flow
-165.48-22.842-43.8-92.47-59.36
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-8.92-4.7-3.99-19.04-12.91-9.73
Sale of Property, Plant & Equipment
---0.060.110.08
Investment in Securities
-350.54-97.13-40.46107.78-206.42-
Investing Cash Flow
-359.46-101.83-44.4588.8-219.22-9.65

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
362.5830.7152.532.6121.45255.79
Other Financing Activities
-0.84-0.3646.3624.88-0.98-21.23
Financing Cash Flow
361.7430.3598.8927.4920.47377.56

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-163.2-94.2896.4472.49-291.22308.55

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-174.39-27.538.01-62.84-105.38-69.1
Free Cash Flow Growth
------
Free Cash Flow Margin
-247.98%-22.23%50.26%---
Free Cash Flow Per Share
-1.79-0.330.51-1.22-2.23-2.76
Levered Free Cash Flow
-124.76-113.0781.97-53.37-72.4-61.29
Unlevered Free Cash Flow
-124.76-113.0781.97-53.37-72.4-61.29

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
-63.71-9.1991.472.47-2.136.29
SEC Filings: 10-K · 10-Q